within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FC02_Isatuximab;

model Isatuximab
  extends Pharmacolibrary.Drugs.ATC.L.L01FC02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FC02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Isatuximab is a monoclonal antibody that targets CD38, a cell surface glycoprotein highly expressed on multiple myeloma cells. It is used for the treatment of adult patients with relapsed or refractory multiple myeloma, typically in combination with other therapies. It is approved by FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with relapsed/refractory multiple myeloma.</p><h4>References</h4><ol><li><p>Simonelli, M, et al., &amp; Massard, C (2022). Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. <i>ESMO open</i> 7(5) 100562–None. DOI:<a href=&quot;https://doi.org/10.1016/j.esmoop.2022.100562&quot;>10.1016/j.esmoop.2022.100562</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35987165/&quot;>https://pubmed.ncbi.nlm.nih.gov/35987165</a></p></li><li><p>Ailawadhi, S, et al., &amp; Moreau, P (2025). Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> None 101200JCO2500744–None. DOI:<a href=&quot;https://doi.org/10.1200/JCO-25-00744&quot;>10.1200/JCO-25-00744</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40459178/&quot;>https://pubmed.ncbi.nlm.nih.gov/40459178</a></p></li><li><p>Martin, TG, et al., &amp; Chari, A (2021). Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> 127(11) 1816–1826. DOI:<a href=&quot;https://doi.org/10.1002/cncr.33448&quot;>10.1002/cncr.33448</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33735504/&quot;>https://pubmed.ncbi.nlm.nih.gov/33735504</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Isatuximab;
